CAJ | 학술논문

尽管手术及化疗技术在近30年有很大改进，但上皮性卵巢癌的病死率依然居妇科肿瘤之首。而铂类耐药卵巢癌由于对以铂类为基础的一线化疗药物耐受，预后更差。现有治疗包括以紫杉醇、托泊替康、多柔比星、吉西他滨为基础的标准化疗，主要针对血管内皮生长因子受体、表皮生长因子受体、血小板衍生生长因子受体、叶酸受体等的单克隆抗体和小分子酪氨酸激酶抑制剂及聚腺苷酸二磷酸核糖转移酶抑制剂等。
진관수술급화료기술재근30년유흔대개진，단상피성란소암적병사솔의연거부과종류지수。이박류내약란소암유우대이박류위기출적일선화료약물내수，예후경차。현유치료포괄이자삼순、탁박체강、다유비성、길서타빈위기출적표준화료，주요침대혈관내피생장인자수체、표피생장인자수체、혈소판연생생장인자수체、협산수체등적단극륭항체화소분자락안산격매억제제급취선감산이린산핵당전이매억제제등。
Despite surgery skill and chemotherapy technology have greatly improved in the past 30 years,the mortality rate of epithelial ovarian cancer ranks first in all gynecological tumors .The prognosis of platinum-resistant ovarian cancer is even worse because of its tolerance to first-line chemotherapy drugs basad on platinum.Currently there are four standard chemotherapy drugs used for the platinum-resistant patients:paclitaxel,topotecan,doxorubicin,gemcitabine.Also targeted therapys may represent the future of platinum-resistant ovarian cancer treatment,and current approaches can be classified into different groups.For exam-ple,some target the vascular endothelial growth factor receptor pathway, epidermal growth factor receptor pathway,platelet-derived growth factor receptor pathway,whereas others are directed against the folate recep-tor pathway,small molecule tyrosine kinase inhibitor,and poly ADP-ribosyl transferase inhibitors.